SEC Form 4
Regeneron Pharmaceuticals Inc (REGN) insider trading
In the 12 months to Oct 24, 2026, 8 REGN insiders reported open-market sales of $16.1M across 16 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $16.1M
- 16 filings · 8 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 14 of 16
- $11.6M of $16.1M sold (72%)
Who traded REGN, and when
- Sale
- Sale, pre-arranged (10b5-1)
REGN daily close from Oct 24, 2025 to Oct 23, 2026, between $577.95 and $852.03, last $805.02. 16 sale and 0 purchase filings by 8 insiders, marked at their filing dates. Christine A. Poon, Director: sold $4.3M across 1 filing, first filed Oct 31, 2025, last Oct 31, 2025. Andrew J. Murphy, Co-Chief Scientific Officer: sold $3.2M across 1 filing, first filed Oct 15, 2026, last Oct 15, 2026. Marion McCourt, EVP Commercial: sold $2.0M across 1 filing, first filed Sep 3, 2026, last Sep 3, 2026. Huda Y. Zoghbi, Director: sold $1.9M across 2 filings, first filed Feb 23, 2026, last Aug 12, 2026. Jason Pitofsky, VP Controller → SVP Controller: sold $1.9M across 2 filings, first filed Nov 10, 2025, last Feb 11, 2026. Bonnie L. Bassler, Director: sold $1.8M across 2 filings, first filed Nov 24, 2025, last Jan 8, 2026. 2 others: sold $1.1M across 7 filings, first filed Feb 11, 2026, last Sep 3, 2026.
Largest mark · tap a row for others
Christine A. Poon · Director
Sale $4,252,745
6,500 shares at $654.27 avg
Filed Oct 31, 2025 · traded Oct 29
Close on filing date $651.80
Christine A. Poon · Director
Director
$4.3M soldAndrew J. Murphy · Co-Chief Scientific Officer
Co-Chief Scientific Officer
$3.2M soldMarion McCourt · EVP Commercial
EVP Commercial
$2.0M soldHuda Y. Zoghbi · Director
Director
$1.9M soldJason Pitofsky · VP Controller → SVP Controller
VP Controller → SVP Controller
$1.9M soldBonnie L. Bassler · Director
Director
$1.8M sold2 others
Combined, one mark per week
$1.1M soldHas Regeneron Pharmaceuticals Inc's CEO sold stock?
No. Leonard S. Schleifer (CEO) made no open-market sales filed as CEO in the last 12 months.
Open-market trades
16 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Christine A. Poon | Director | $4.3M | — | 1 | — | |
| Andrew J. Murphy | Co-Chief Scientific Officer | $3.2M | — | 1 | 100% of sales | |
| Marion McCourt | EVP Commercial | $2.0M | — | 1 | 100% of sales | |
| Huda Y. Zoghbi | Director | $1.9M | — | 2 | 100% of sales | |
| Jason Pitofsky | VP Controller → SVP Controller | $1.9M | — | 2 | 85% of sales | |
| Bonnie L. Bassler | Director | $1.8M | — | 2 | 100% of sales | |
| Kathryn Guarini | Director | $660.0K | — | 2 | 100% of sales | |
| Arthur F. Ryan | Director | $434.7K | — | 5 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Andrew J. Murphy Co-Chief Scientific Officer | SalePre-arranged (10b5-1) | 4,147 | $772.70 | $3.2M | 51,885 | |
traded | Marion McCourt EVP Commercial | SalePre-arranged (10b5-1) | 2,346 | $853.56 | $2.0M | 12,003 | |
traded | Kathryn Guarini Director | SalePre-arranged (10b5-1) | 400 | $850.00 | $340.0K | 603 | |
traded | Huda Y. Zoghbi Director | SalePre-arranged (10b5-1) | 800 | $800.00 | $640.0K | 1,703 | |
traded | Kathryn Guarini Director | SalePre-arranged (10b5-1) | 400 | $800.00 | $320.0K | 603 | |
traded | Arthur F. Ryan Director | SalePre-arranged (10b5-1) | 200 | $650.15 | $130.0K | 17,303 | |
traded | Arthur F. Ryan Director | SalePre-arranged (10b5-1) | 100 | $705.24 | $70.5K | 17,505 | |
traded | Arthur F. Ryan Director | SalePre-arranged (10b5-1) | 100 | $777.27 | $77.7K | 17,656 | |
traded | Arthur F. Ryan Director | SalePre-arranged (10b5-1) | 100 | $785.50 | $78.5K | 17,789 | |
traded | Huda Y. Zoghbi Director | SalePre-arranged (10b5-1) | 1,638 | $781.33 | $1.3M | 3,292 | |
traded | Arthur F. Ryan Director | SalePre-arranged (10b5-1) | 100 | $778.53 | $77.9K | 17,892 | |
traded | Jason Pitofsky SVP Controller | SalePre-arranged (10b5-1) | 2,036 | $778.52 | $1.6M | 4,326 | |
traded | Bonnie L. Bassler Director | SalePre-arranged (10b5-1) | 1,500 | $800.00 | $1.2M | 1,703 | |
traded | Bonnie L. Bassler Director | SalePre-arranged (10b5-1) | 760 | $750.00 | $570.0K | 1,548 | |
traded | Jason Pitofsky VP Controller | Sale | 431 | $651.43 | $280.8K | 4,233 | |
traded | Christine A. Poon Director | Sale | 6,500 | $654.27 | $4.3M | 5,467 |
GET /stocks/filings/vX/form-4?tickers=REGN&filing_date.gte=2025-10-24&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"REGN"
],
"issuer_cik": "0000872589",
"owner_cik": "0001796226",
"accession_number": "0001796226-26-000002",
"form_type": "4",
"filing_date": "2026-10-15",
"period_of_report": "2026-10-13",
"issuer_name": "REGENERON PHARMACEUTICALS, INC.",
"issuer_trading_symbol": "REGN",
"owner_name": "MURPHY ANDREW J",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Co-Chief Scientific Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-14",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 380,
"transaction_price_per_share": 779.59,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 48346,
"transaction_value": 296244.2,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 7, 2026."
},
{
"id": "F20",
"description": "Represents volume-weighted average price of sales of 380 shares of Company stock on October 14, 2026 at prices ranging from $779.00 to $779.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 14, 2026 at each separate price."
}
]
},
{
"tickers": [
"REGN"
],
"issuer_cik": "0000872589",
"owner_cik": "0001796226",
"accession_number": "0001796226-26-000002",
"form_type": "4",
"filing_date": "2026-10-15",
"period_of_report": "2026-10-13",
"issuer_name": "REGENERON PHARMACEUTICALS, INC.",
"issuer_trading_symbol": "REGN",
"owner_name": "MURPHY ANDREW J",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Co-Chief Scientific Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-14",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 6,
"transaction_price_per_share": 753.76,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 51974,
"transaction_value": 4522.5599999999995,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 7, 2026."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 56 records
- Option exercises19 records
- Tax withholding19 records
- Grants and awards17 records
- Gifts1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
Build this yourself
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for REGN every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.